1.

Ticagrelor Versus Clopidogrel in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Hypothermia: A Randomized Study.

In contrast to clopidogrel, that is not an effective antiplatelet drug in therapeutically hypothermic patients surviving out-of-hospital cardiac arrest and undergoing percutaneous coronary intervention, ticagrelor adequately supressed platelet reactiviaty already after 2 hours.

COBISS.SI-ID: 3419308

2.

Low-dose fluvastatin and valsartan rejuvenate the arterial wall through telomerase activity increase in the middle-aged men

Low dose combination of fluvastatin and valsartan significantly increases the telomerase activity that is associated with improved functional and structural characteristics of the arterial wall.

COBISS.SI-ID: 2061947

3.

Rotational thromboelastometry in ex vivo samples from routine clinical practice patients receiving dabigatran

In this study on a large group of patients, dabigatran, depending on concentration, prolonged c clotting time of all ROTEM® tests INTEM, EXTEM FIBTEM and APTEM. All ROTEM® tests reliably detected dabigatran concentrations above 255 μg/L and could provide a quicker anticoagulant assessment compared to APTT in an emergency situation.

COBISS.SI-ID: 3449260

4.

Risk of thromboembolic events in patients with non-valvular atrial fibrillation after dabigatran or rivaroxaban discontinuation

Dabigatran and rivaroxaban offered good protection against thromboembolic events on-treatment, but interruption of NOAC treatment increased the short-term thromboembolic risk more than 20-fold, way above the baseline CHADS2 risk. The most vulnerable sub-group were patients with bleeding

COBISS.SI-ID: 3118764

5.

Deep vein thrombosis and pulmonary embolism in the apixaban era

It is an rewiev on efficacy and advantages of new oral anticoagulant drugs in comparison to standard therapeutic protocol using heparin and warfarin.

COBISS.SI-ID: 2831020